Iheezo is a drug owned by Harrow Eye Llc. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 15, 2038. Details of Iheezo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10792271 | Topical formulations of chloroprocaine and methods of using same |
Sep, 2038
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Iheezo's patents.
Latest Legal Activities on Iheezo's Patents
Given below is the list of recent legal activities going on the following patents of Iheezo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 Apr, 2024 | US10792271 |
| Recordation of Patent Grant Mailed Critical | 06 Oct, 2020 | US10792271 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Oct, 2020 | US10792271 |
| Email Notification Critical | 17 Sep, 2020 | US10792271 |
| Issue Notification Mailed Critical | 16 Sep, 2020 | US10792271 |
| Dispatch to FDC | 04 Sep, 2020 | US10792271 |
| Application Is Considered Ready for Issue Critical | 04 Sep, 2020 | US10792271 |
| Issue Fee Payment Received Critical | 01 Sep, 2020 | US10792271 |
| Issue Fee Payment Verified Critical | 01 Sep, 2020 | US10792271 |
| Electronic Review Critical | 20 Aug, 2020 | US10792271 |
FDA has granted several exclusivities to Iheezo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Iheezo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Iheezo.
Exclusivity Information
Iheezo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Iheezo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 27, 2025 |
US patents provide insights into the exclusivity only within the United States, but Iheezo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Iheezo's family patents as well as insights into ongoing legal events on those patents.
Iheezo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Iheezo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 15, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Iheezo Generic API suppliers:
Chloroprocaine Hydrochloride is the generic name for the brand Iheezo. 2 different companies have already filed for the generic of Iheezo, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Iheezo's generic
Alternative Brands for Iheezo
Iheezo which is used for inducing ocular anesthesia., has several other brand drugs using the same active ingredient (Chloroprocaine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| B Braun Medical Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Chloroprocaine Hydrochloride, Iheezo's active ingredient. Check the complete list of approved generic manufacturers for Iheezo
About Iheezo
Iheezo is a drug owned by Harrow Eye Llc. It is used for inducing ocular anesthesia. Iheezo uses Chloroprocaine Hydrochloride as an active ingredient. Iheezo was launched by Harrow Eye in 2022.
Approval Date:
Iheezo was approved by FDA for market use on 27 September, 2022.
Active Ingredient:
Iheezo uses Chloroprocaine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Chloroprocaine Hydrochloride ingredient
Treatment:
Iheezo is used for inducing ocular anesthesia.
Dosage:
Iheezo is available in gel form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3% | GEL | Prescription | OPHTHALMIC |